Contracts Finder

NHS Framework for the North of England, Branded Medicine

NHS England

Awarded

goods

SME-friendly

Framework agreement

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority

NHS England

nhs

Region

Runcorn

Sector

Healthcare & Medical

Contract value

£431,836,170ex VAT

Submissions closed

20 October 2021

Published

8 August 2023

Procurement

Contract period

1 March 2022 - 29 February 2024

2 years

Procedure type

Open procedure (above threshold)

CPV classifications

33600000 Pharmaceutical products

What happened

Description

Offer reference number: CM/PHR/20/5600

CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Awarded suppliers (31)

Suppliers

Thornton and Ross Ltd
Janssen-Cilag Ltd
Biogen
Merck Serono Limited
Celltrion Healthcare United Kingdom Limited
Bristol Myers Squibb
AstraZeneca
UL Global Pharma
GlaxoSmithKline UK Limited
Roche Products Ltd
Bayer Ltd
Merck Sharpe & Dohme (UK) Limited
Pfizer Ltd
Accord-UK Ltd
Novo Nordisk
Sandoz Ltd
Napp Pharmaceuticals Ltd
Eli Lilly & Company Ltd
Ipsen
Amgen Ltd
Aventis Pharma ltd t/a Sanofi
UCB Pharma Ltd
Teva UK Limited
Zentiva Pharma UK Ltd
CST Pharma Limited
Takeda UK Ltd
Mylan
Gilead Sciences Limited
Organon Pharmaceuticals UK Ltd
Gedeon Richter UK Ltd
Sobi (Swedish Orphan Biovitrum Ltd)

Award value

£238,913,892

Award date

7 February 2022

Contact

Address

2nd Floor Rutland House, Runcorn, WA7 2ES

Contact name

Giorgie Rushton

[email protected]

Identifiers

Buyer reference

CF-0634100D0O000000rwimUAA

Notice ID

521ac6ee-777d-4ac4-8c5c-88045d5101fd-670252

OCID

ocds-b5fd17-8f156716-6a74-476b-ac41-29b32bb73599

Explore related tenders

Other tenders from NHS England

View all →

Secondary Care Medicines Data Pre-Market Engagement£6,750,000

Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service

Targeted Prostate Cancer Screening Programme - MRI Reporting Service

Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000

Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-8f156716-6a74-476b-ac41-29b32bb73599 • Added 4 October 2026